https://innovivaspecialtytherapeutics.com/publication/efficacy-and-safety-of-eravacycline-in-obese-patients-a-post-hoc-analysis-of-pooled-data-from-the-ignite1-and-ignite4-clinical-trials/2025-06-11T10:44:26-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-eravacycline-compared-with-tigecycline-against-carbapenem-resistant-enterobacteriaceae/2025-06-11T10:45:16-07:00https://innovivaspecialtytherapeutics.com/publication/eravacycline-a-new-treatment-option-for-complicated-intra-abdominal-infections-in-the-age-of-multidrug-resistance/2025-06-11T10:46:23-07:00https://innovivaspecialtytherapeutics.com/publication/assessment-of-the-physical-compatibility-of-eravacycline-and-common-parenteral-drugs-during-simulated-y-site-administration/2025-06-11T10:47:29-07:00https://innovivaspecialtytherapeutics.com/publication/activity-of-cefiderocol-cfdc-ceftazidime-avibactam-cza-and-eravacycline-erv-against-carbapenem-resistant-cr-e-coli-isolates-from-the-us-clonal-background-resistance-genes-and-co-resistan/2025-06-11T10:48:33-07:00https://innovivaspecialtytherapeutics.com/publication/eravacycline-a-review-in-complicated-intra-abdominal-infections/2025-06-11T10:48:59-07:00https://innovivaspecialtytherapeutics.com/publication/ignite4-results-of-a-phase-3-randomized-multicenter-prospective-trial-of-eravacycline-vs-meropenem-in-the-treatment-of-complicated-intraabdominal-infections/2025-06-11T10:49:24-07:00https://innovivaspecialtytherapeutics.com/publication/randomized-double-blind-placebo-controlled-studies-of-the-safety-and-pharmacokinetics-of-single-and-multiple-ascending-doses-of-eravacycline/2025-06-11T10:50:08-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-susceptibility-of-%ce%b2-lactamase-producing-carbapenem-resistant-enterobacteriaceae-cre-to-eravacycline/2025-06-11T10:50:37-07:00https://innovivaspecialtytherapeutics.com/publication/assessment-of-in-vivo-efficacy-of-eravacycline-against-enterobacteriaceae-exhibiting-various-resistance-mechanisms-a-dose-ranging-study-and-pharmacokinetic-pharmacodynamic-analysis/2025-06-11T10:51:12-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-eravacycline-and-comparator-antimicrobials-against-143-recent-strains-of-bacteroides-species/2025-06-11T10:52:24-07:00https://innovivaspecialtytherapeutics.com/publication/in-vivo-pharmacodynamic-target-assessment-of-eravacycline-against-escherichia-coli-in-a-murine-thigh-infection-model/2025-06-11T10:55:05-07:00https://innovivaspecialtytherapeutics.com/publication/assessing-the-efficacy-and-safety-of-eravacycline-vs-ertapenem-in-complicated-intra-abdominal-infections-in-the-investigating-gram-negative-infections-treated-with-eravacycline-ignite-1-trial-a-ran/2025-06-11T10:57:49-07:00https://innovivaspecialtytherapeutics.com/publication/a-divergent-route-to-eravacycline/2025-06-11T10:58:09-07:00https://innovivaspecialtytherapeutics.com/publication/phase-2-randomized-double-blind-study-of-the-efficacy-and-safety-of-two-dose-regimens-of-eravacycline-versus-ertapenem-for-adult-community-acquired-complicated-intra-abdominal-infections/2025-06-11T09:56:57-07:00https://innovivaspecialtytherapeutics.com/publication/process-rd-of-eravacycline-the-first-fully-synthetic-fluorocycline-in-clinical-development/2025-06-11T09:56:31-07:00https://innovivaspecialtytherapeutics.com/publication/target-and-resistance-based-mechanistic-studies-with-tp-434-a-novel-fluorocycline-antibiotic/2025-06-11T09:56:14-07:00https://innovivaspecialtytherapeutics.com/publication/fluorocyclines-1-7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline-a-potent-broad-spectrum-antibacterial-agent/2025-06-11T09:55:53-07:00https://innovivaspecialtytherapeutics.com/publication/serum-renin-and-major-adverse-kidney-events-in-critically-ill-patients-a-multicenter-prospective-study/2025-06-11T09:48:44-07:00https://innovivaspecialtytherapeutics.com/publication/evaluating-the-evidence-for-angiotensin-ii-for-the-treatment-of-vasoplegia-in-critically-ill-cardiothoracic-surgery-patients/2025-06-11T11:01:51-07:00https://innovivaspecialtytherapeutics.com/publication/a-multicenter-observational-cohort-study-of-angiotensin-ii-in-shock/2025-06-11T11:02:18-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-infusion-for-shock-a-multicenter-study-of-postmarketing-use/2025-06-11T09:49:26-07:00https://innovivaspecialtytherapeutics.com/publication/impaired-angiotensin-ii-type-1-receptor-signaling-contributes-to-sepsis-induced-acute-kidney-injury/2025-06-11T11:02:40-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-for-critically-ill-patients-with-shock-after-heart-transplant/2025-06-11T11:03:02-07:00https://innovivaspecialtytherapeutics.com/publication/treatment-with-angiotensin-ii-is-associated-with-rapid-blood-pressure-response-and-vasopressor-sparing-in-patients-with-vasoplegia-after-cardiac-surgery-a-post-hoc-analysis-of-angiotensin-ii-for-the/2025-06-11T09:49:50-07:00https://innovivaspecialtytherapeutics.com/publication/renin-and-survival-in-patients-given-angiotensin-ii-for-catecholamine-resistant-vasodilatory-shock/2025-06-11T11:03:29-07:00https://innovivaspecialtytherapeutics.com/publication/use-of-angiotensin-ii-in-severe-vasoplegia-after-left-pneumonectomy-requiring-cardiopulmonary-bypass-a-renin-response-analysis/2025-06-11T11:03:54-07:00https://innovivaspecialtytherapeutics.com/publication/covid-19-and-the-raas-a-potential-role-for-angiotensin-ii/2025-06-11T11:04:09-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-for-the-treatment-of-distributive-shock-in-the-intensive-care-unit-a-us-costeffectiveness-analysis/2025-06-11T11:04:34-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-i-and-angiotensin-ii-concentrations-and-their-ratio-in-catecholamine-resistant-vasodilatory-shock/2025-06-11T11:05:07-07:00https://innovivaspecialtytherapeutics.com/publication/sensitivity-to-angiotensin-ii-dose-in-patients-with-vasodilatory-shock-a-prespecified-analysis-of-the-athos-3-trial/2025-06-11T11:05:38-07:00https://innovivaspecialtytherapeutics.com/publication/outcomes-in-patients-with-vasodilatory-shock-and-renal-replacement-therapy-treated-with-intravenous-angiotensin-ii/2025-06-11T11:06:14-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-for-the-treatment-of-vasodilatory-shock/2025-06-11T11:06:41-07:00https://innovivaspecialtytherapeutics.com/publication/clinical-experience-with-iv-angiotensin-ii-administration-a-systematic-review-of-safety/2025-06-11T11:07:05-07:00https://innovivaspecialtytherapeutics.com/publication/intravenous-angiotensin-ii-for-the-treatment-of-high-output-shock-athos-trial-a-pilot-study/2025-06-11T09:58:02-07:00https://innovivaspecialtytherapeutics.com/publication/gyrb-in-silico-mining-in-27-151-global-gonococcal-genomes-from-1928-2021-combined-with-zoliflodacin-in-vitro-testing-of-71-international-gonococcal-isolates-with-different-gyrb-parc-a/2025-06-11T09:36:17-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacodynamic-evaluation-of-zoliflodacin-treatment-of-neisseria-gonorrhoeae-strains-with-amino-acid-substitutions-in-the-zoliflodacin-target-gyrb-using-a-dynamic-hollow-fiber-infection-model/2025-06-11T09:36:55-07:00https://innovivaspecialtytherapeutics.com/publication/high-in-vitro-susceptibility-to-the-first-in-class-spiropyrimidinetrione-zoliflodacin-among-consecutive-clinical-neisseria-gonorrhoeae-isolates-from-thailand-and-south-africa/2025-06-11T09:39:36-07:00https://innovivaspecialtytherapeutics.com/publication/high-susceptibility-to-zoliflodacin-and-conserved-target-gyrb-for-zoliflodacin-among-1209-consecutive-clinical-neisseria-gonorrhoeae-isolates-from-25-european-countries-2018/2025-06-11T09:39:19-07:00https://innovivaspecialtytherapeutics.com/publication/thorough-qt-study-to-evaluate-the-effect-of-zoliflodacin-a-novel-therapeutic-for-gonorrhea-on-cardiac-repolarization-in-healthy-adults/2025-06-11T09:37:31-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacodynamic-evaluation-of-dosing-bacterial-kill-and-resistance-suppression-for-zoliflodacin-against-neisseria-gonorrhoeae-in-a-dynamic-hollow-fiber-infection-model/2025-06-11T09:38:18-07:00https://innovivaspecialtytherapeutics.com/publication/susceptibility-trends-of-zoliflodacin-against-multidrug-resistant-neisseria-gonorrhoeae-clinical-isolates-in-nanjing-china-2014-to-2018/2025-06-11T09:38:44-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacokinetic-pharmacodynamic-considerations-for-new-and-current-therapeutic-drugs-for-uncomplicated-gonorrhoea-challenges-and-opportunities/2025-06-11T09:50:55-07:00https://innovivaspecialtytherapeutics.com/publication/zoliflodacin-an-oral-spiropyrimidinetrione-antibiotic-for-the-treatment-of-neisseria-gonorrheae-including-multi-drug-resistant-isolates/2025-06-11T09:51:20-07:00https://innovivaspecialtytherapeutics.com/publication/determination-of-mic-quality-control-ranges-for-the-novel-gyrase-inhibitor-zoliflodacin/2025-06-11T09:51:42-07:00https://innovivaspecialtytherapeutics.com/publication/single-dose-zoliflodacin-etx0914-for-treatment-of-urogenital-gonorrhea/2025-06-11T09:52:23-07:00https://innovivaspecialtytherapeutics.com/publication/single-dose-pharmacokinetics-excretion-and-metabolism-of-zoliflodacin-a-novel-spiropyrimidinetrione-antibiotic-in-healthy-volunteers/2025-06-11T09:52:03-07:00https://innovivaspecialtytherapeutics.com/publication/antimicrobial-resistance-in-neisseria-gonorrhoeae-proceedings-of-the-star-sexually-transmitted-infection-clinical-trial-group-programmatic-meeting/2025-07-21T13:41:15-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-zoliflodacin-etx0914-against-macrolide-resistant-fluoroquinolone-resistant-and-antimicrobial-susceptible-mycoplasma-genitalium-strains/2025-06-11T09:52:54-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-growth-of-multidrug-resistant-neisseria-gonorrhoeae-isolates-is-inhibited-by-etx0914-a-novel-spiropyrimidinetrione/2025-06-11T09:53:24-07:00https://innovivaspecialtytherapeutics.com/publication/effect-of-susceptibility-testing-conditions-on-the-in-vitro-antibacterial-activity-of-etx0914/2025-06-11T09:54:10-07:00https://innovivaspecialtytherapeutics.com/publication/absorption-distribution-metabolism-and-elimination-of-14c-etx0914-a-novel-inhibitor-of-bacterial-type-ii-topoisomerases-in-rodents/2025-06-11T09:53:50-07:00https://innovivaspecialtytherapeutics.com/publication/genetic-resistance-determinants-in-vitro-time-kill-curve-analysis-and-pharmacodynamic-functions-for-the-novel-topoisomerase-ii-inhibitor-etx0914-azd0914-in-neisseria-gonorrhoeae/2025-06-11T09:59:18-07:00https://innovivaspecialtytherapeutics.com/publication/multidrug-resistant-neisseria-gonorrhoeae-isolates-from-nanjing-china-are-sensitive-to-killing-by-a-novel-dna-gyrase-inhibitor-etx0914-azd0914/2025-06-11T10:00:05-07:00https://innovivaspecialtytherapeutics.com/publication/update-on-treatment-options-for-gonococcal-infections/2025-06-11T09:58:58-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-azd0914-a-novel-bacterial-dna-gyrase-topoisomerase-iv-inhibitor-against-clinically-relevant-gram-positive-and-fastidious-gram-negative-pathogens/2025-06-11T09:58:42-07:00https://innovivaspecialtytherapeutics.com/publication/responding-to-the-challenge-of-untreatable-gonorrhea-etx0914-a-first-in-class-agent-with-a-distinct-mechanism-of-action-against-bacterial-type-ii-topoisomerases/2025-06-11T09:54:51-07:00https://innovivaspecialtytherapeutics.com/publication/inhibition-of-neisseria-gonorrhoeae-type-ii-topoisomerases-by-the-novel-spiropyrimidinetrione-azd0914/2025-07-21T13:38:37-07:00https://innovivaspecialtytherapeutics.com/publication/discovery-of-novel-dna-gyrase-inhibiting-spiropyrimidinetriones-benzisoxazole-fusion-with-n-linked-oxazolidinone-substituents-leading-to-a-clinical-candidate-etx0914/2025-06-11T09:55:03-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-antibacterial-activity-of-azd0914-against-human-mycoplasmas-and-ureaplasmas/2025-06-11T09:55:27-07:00https://innovivaspecialtytherapeutics.com/publication/high-in-vitro-susceptibility-to-the-novel-spiropyrimidinetrione-etx0914-azd0914-among-873-contemporary-clinical-neisseria-gonorrhoeae-isolates-from-21-european-countries-from-2012-to-2014/2025-06-11T10:01:11-07:00https://innovivaspecialtytherapeutics.com/publication/characterization-of-the-novel-dna-gyrase-inhibitor-azd0914-low-resistance-potential-and-lack-of-cross-resistance-in-neisseria-gonorrhoeae/2025-06-11T09:58:23-07:00https://innovivaspecialtytherapeutics.com/publication/high-in-vitro-activity-of-the-novel-spiropyrimidinetrione-azd0914-a-dna-gyrase-inhibitor-against-multidrug-resistant-neisseria-gonorrhoeae-isolates-suggests-a-new-effective-option-for-oral-treatment/2025-06-11T09:57:43-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-azd0914-a-novel-dna-gyrase-inhibitor-against-chlamydia-trachomatis-and-chlamydia-pneumoniae/2025-06-11T10:05:22-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-antibacterial-activity-of-azd0914-a-new-spiropyrimidinetrione-dna-gyrase-topoisomerase-inhibitor-with-potent-activity-against-gram-positive-fastidious-gram-negative-and-atypical-bacteria/2025-06-11T10:04:40-07:00https://innovivaspecialtytherapeutics.com/publication/novel-dna-gyrase-inhibiting-spiropyrimidinetriones-with-a-benzisoxazole-scaffold-sar-and-in-vivo-characterization/2025-06-11T10:05:02-07:00https://innovivaspecialtytherapeutics.com/publication/synthesis-of-a-tetrahydronaphthyridine-spiropyrimidinetrione-dna-gyrase-inhibiting-antibacterial-agent-differential-substitution-at-all-five-carbon-atoms-of-pyridine/2025-06-11T10:07:52-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-sulbactam-durlobactam-against-global-isolates-of-acinetobacter-baumannii-calcoaceticus-complex-collected-from-2016-to-2021/2025-06-11T07:55:29-07:00https://innovivaspecialtytherapeutics.com/publication/durlobactam-a-new-diazabicyclooctane-%ce%b2-lactamase-inhibitor-for-the-treatment-of-acinetobacter-infections-in-combination-with-sulbactam/2025-06-11T07:55:56-07:00https://innovivaspecialtytherapeutics.com/publication/a-randomized-double-blind-placebo-and-positive-controlled-crossover-study-of-the-effects-of-durlobactam-on-cardiac-repolarization-in-healthy-subjects/2025-06-11T07:56:13-07:00https://innovivaspecialtytherapeutics.com/publication/safety-pharmacokinetics-and-drug-drug-interaction-potential-of-intravenous-durlobactam-a-%ce%b2-lactamase-inhibitor-in-healthy-subjects/2025-06-11T07:56:56-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-sulbactam-durlobactam-against-global-isolates-of-carbapenem-resistant-acinetobacter-baumannii/2025-06-11T07:57:24-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-sulbactam-durlobactam-against-clinical-isolates-of-acinetobacter-baumannii-collected-in-china/2025-06-11T07:57:47-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacokinetics-and-tolerability-of-intravenous-sulbactam-durlobactam-with-imipenem-cilastatin-in-hospitalized-adults-with-complicated-urinary-tract-infections-including-acute-pyelonephritis/2025-06-11T07:58:35-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-sulbactam-durlobactam-against-acinetobacter-baumannii-calcoaceticus-complex-isolates-collected-globally-in-2016-and-2017/2025-06-11T07:58:04-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacokinetics-safety-and-tolerability-of-intravenous-durlobactam-and-sulbactam-in-subjects-with-renal-impairment-and-healthy-matched-control-subjects/2025-06-11T07:59:12-07:00https://innovivaspecialtytherapeutics.com/publication/targeting-multidrug-resistant-acinetobacter-spp-sulbactam-and-the-diazabicyclooctenone-%ce%b2-lactamase-inhibitor-etx2514-as-a-novel-therapeutic-agent/2025-06-11T07:59:37-07:00https://innovivaspecialtytherapeutics.com/publication/plasma-and-intrapulmonary-concentrations-of-etx2514-and-sulbactam-following-intravenous-administration-of-etx2514sul-to-healthy-adult-subjects/2025-06-11T08:00:10-07:00https://innovivaspecialtytherapeutics.com/publication/acinetobacter-baumannii-ompa-is-a-selective-antibiotic-permeant-porin/2025-06-11T08:01:24-07:00https://innovivaspecialtytherapeutics.com/publication/frequency-and-mechanism-of-spontaneous-resistance-to-sulbactam-combined-with-the-novel-%ce%b2-lactamase-inhibitor-etx2514-in-clinical-isolates-of-acinetobacter-baumannii/2025-06-11T08:00:41-07:00https://innovivaspecialtytherapeutics.com/publication/kinetics-of-sulbactam-hydrolysis-by-%ce%b2-lactamases-and-kinetics-of-%ce%b2-lactamase-inhibition-by-sulbactam/2025-06-11T08:02:15-07:00https://innovivaspecialtytherapeutics.com/publication/reversibility-of-covalent-broad-spectrum-serine-%ce%b2-lactamase-inhibition-by-the-diazabicyclooctenone-etx2514/2025-06-11T08:02:49-07:00https://innovivaspecialtytherapeutics.com/publication/etx2514-is-a-broad-spectrum-%ce%b2-lactamase-inhibitor-for-the-treatment-of-drug-resistant-gram-negative-bacteria-including-acinetobacter-baumannii/2025-06-11T08:03:27-07:00https://innovivaspecialtytherapeutics.com/publication/molecular-mechanisms-of-sulbactam-antibacterial-activity-and-resistance-determinants-in-acinetobacter-baumannii/2025-06-11T08:04:05-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-eravacycline-and-comparator-agents-against-bacterial-pathogens-isolated-from-patients-with-cancer/2025-06-11T10:43:10-07:00https://innovivaspecialtytherapeutics.com/publication/initiating-angiotensin-ii-at-lower-vasopressor-doses-in-vasodilatory-shock-an-exploratory-post-hoc-analysis-of-the-athos-3-clinical-trial/2025-06-11T09:47:53-07:00https://innovivaspecialtytherapeutics.com/publication/effects-of-angiotensin-ii-in-the-management-of-perioperative-hypotension-in-kidney-transplant-recipients/2025-06-11T09:46:03-07:00https://innovivaspecialtytherapeutics.com/publication/a-double-blind-randomised-feasibility-trial-of-angiotensin-2-in-cardiac-surgery/2025-06-11T09:47:03-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-enhances-bacterial-clearance-via-myeloid-signaling-in-a-murine-sepsis-model/2025-06-11T09:46:43-07:00https://innovivaspecialtytherapeutics.com/publication/efficacy-and-safety-of-sulbactam-durlobactam-versus-colistin-for-the-treatment-of-patients-with-serious-infections-caused-by-acinetobacter-baumannii-calcoaceticus-complex-a-multicentre-randomised-a/2025-06-11T07:55:03-07:00https://innovivaspecialtytherapeutics.com/publication/sulbactam-durlobactam-a-step-forward-in-treating-carbapenem-resistant-acinetobacter-baumannii-crab-infections/2025-06-11T07:54:38-07:00https://innovivaspecialtytherapeutics.com/publication/why-the-renin-angiotensin-aldosterone-system-raas-in-critically-ill-patients-can-no-longer-be-ignored/2025-06-11T09:46:19-07:00https://innovivaspecialtytherapeutics.com/publication/the-role-of-angiotensin-ii-in-poisoning-induced-shock-a-review/2025-06-11T09:45:24-07:00https://innovivaspecialtytherapeutics.com/publication/myocardial-effects-of-angiotensin-ii-compared-to-norepinephrine-in-an-animal-model-of-septic-shock/2025-06-11T09:45:03-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-for-vasodilatory-hypotension-in-patients-requiring-mechanical-circulatory-support/2025-06-11T09:44:35-07:00https://innovivaspecialtytherapeutics.com/publication/the-association-between-angiotensin-ii-and-renin-kinetics-in-patients-after-cardiac-surgery/2025-06-11T09:44:09-07:00https://innovivaspecialtytherapeutics.com/publication/a-pilot-study-of-angiotensin-ii-as-primary-vasopressor-in-critically-ill-adults-with-vasodilatory-hypotension-the-aramis-study/2025-06-11T11:01:14-07:00https://innovivaspecialtytherapeutics.com/publication/trajectory-of-pao2-fio2-ratio-in-shock-after-angiotensin-ii/2025-06-11T11:00:51-07:00https://innovivaspecialtytherapeutics.com/publication/is-it-time-to-reconsider-the-concept-of-salvage-therapy-in-refractory-shock/2025-06-11T10:58:49-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-for-the-treatment-of-refractory-shock-a-matched-analysis/2025-06-11T10:59:14-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-in-liver-transplantation-anglt-1-protocol-of-a-randomised-double-blind-placebo-controlled-trial/2025-06-11T10:59:37-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-treatment-is-associated-with-improved-oxygenation-in-ards-patients-with-refractory-vasodilatory-shock/2025-06-11T10:42:17-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii/2025-06-11T10:34:27-07:00https://innovivaspecialtytherapeutics.com/publication/dysfunction-of-the-renin-angiotensin-aldosterone-system-in-human-septic-shock/2025-06-11T10:20:45-07:00https://innovivaspecialtytherapeutics.com/publication/renin-levels-and-angiotensin-ii-responsiveness-in-vasopressor-dependent-hypotension/2025-06-11T10:31:13-07:00https://innovivaspecialtytherapeutics.com/publication/plasma-renin-as-a-novel-prognostic-biomarker-of-sepsis-associated-acute-respiratory-distress-syndrome/2025-06-11T10:32:27-07:00https://innovivaspecialtytherapeutics.com/publication/renin-as-a-prognostic-marker-in-intensive-care-and-perioperative-settings-a-scoping-review-2/2025-06-11T11:00:02-07:00https://innovivaspecialtytherapeutics.com/publication/clinical-response-to-third-line-angiotensin-ii-vs-epinephrine-in-septic-shock-a-propensity-matched-cohort-study/2025-06-11T10:16:26-07:00https://innovivaspecialtytherapeutics.com/publication/a-pilot-study-of-renin-guided-angiotensin-ii-infusion-to-reduce-kidney-stress-after-cardiac-surgery/2025-06-11T09:40:51-07:00https://innovivaspecialtytherapeutics.com/publication/antimicrobial-susceptibility-of-baseline-neisseria-gonorrhoeae-isolates-from-participants-recruited-in-the-global-zoliflodacin-phase-3-randomised-controlled-trial/2025-06-11T09:33:53-07:00https://innovivaspecialtytherapeutics.com/publication/safety-profile-of-oral-zoliflodacin-for-uncomplicated-gonorrhoea-in-a-phase-3-trial/2025-06-11T09:34:37-07:00https://innovivaspecialtytherapeutics.com/publication/the-formulation-of-zoliflodacin-for-commercial-use-is-bioequivalent-to-the-phase-3-pivotal-trial-formulation-in-fed-and-fasted-states/2025-06-11T09:31:47-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacokinetics-of-zoliflodacin-in-healthy-participants-in-the-presence-of-itraconazole-suggest-no-clinically-meaningful-cyp3a4-mediated-drug-drug-interactions/2025-06-11T09:31:07-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-antibacterial-activity-of-sulbactam-durlobactam-in-combination-with-other-antimicrobial-agents-against-acinetobacter-baumannii-calcoaceticus-complex/2025-06-11T07:54:09-07:00https://innovivaspecialtytherapeutics.com/publication/comparing-novel-antibiotics-and-carbapenems-for-complicated-intra-abdominal-infections-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/2025-06-11T09:30:39-07:00https://innovivaspecialtytherapeutics.com/publication/omparing-novel-antibiotics-and-carbapenems-for-complicated-intra-abdominal-infections-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/2025-06-11T09:42:19-07:00https://innovivaspecialtytherapeutics.com/publication/clinical-pharmacokinetics-and-pharmacodynamics-of-eravacycline/2025-06-11T09:30:09-07:00https://innovivaspecialtytherapeutics.com/publication/antibiotic-susceptibility-of-ndm-producing-enterobacterales-collected-in-the-united-states-in-2017-and-2018-2/2025-06-11T09:29:34-07:00https://innovivaspecialtytherapeutics.com/publication/the-efficacy-and-safety-of-eravacycline-compared-with-current-clinically-common-antibiotics-in-the-treatment-of-adults-with-complicated-intra-abdominal-infections-a-bayesian-network-meta-analysis/2025-06-11T09:28:58-07:00https://innovivaspecialtytherapeutics.com/publication/comparative-in-vitro-activities-of-omadacycline-eravacycline-and-tigecycline-against-non-esbl-producing-esbl-producing-and-carbapenem-resistant-isolates-of-k-pneumoniae/2025-06-11T09:28:33-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-antimicrobial-activity-and-resistance-mechanisms-of-the-new-generation-tetracycline-agents-eravacycline-omadacycline-and-tigecycline-against-clinical-staphylococcus-aureus-i/2025-06-11T09:28:18-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-imipenem-relebactam-meropenem-vaborbactam-ceftazidime-avibactam-and-comparators-on-carbapenem-resistant-non-carbapenemase-producing-enterobacterales/2025-06-11T09:27:36-07:00https://innovivaspecialtytherapeutics.com/publication/carbapenem-resistant-klebsiella-pneumoniae-virulence-factors-molecular-epidemiology-and-latest-updates-in-treatment-options/2025-06-11T09:25:32-07:00https://innovivaspecialtytherapeutics.com/publication/multicenter-clinical-evaluation-of-etest-eravacycline-for-susceptibility-testing-of-enterobacteriaceae-and-enterococci/2025-06-11T09:26:43-07:00https://innovivaspecialtytherapeutics.com/publication/efficacy-safety-and-tolerability-of-antimicrobial-agents-for-complicated-intra-abdominal-infection-a-systematic-review-and-network-meta-analysis/2025-06-11T09:26:19-07:00https://innovivaspecialtytherapeutics.com/publication/comparative-activities-of-novel-therapeutic-agents-against-molecularly-characterized-clinical-carbapenem-resistant-enterobacterales-isolates/2025-06-11T09:24:56-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-antibacterial-activity-of-sulbactam-durlobactam-in-combination-with-other-antimicrobial-agents-against-acinetobacter-baumannii-calcoaceticus-complex-2/2025-06-11T07:53:22-07:00https://innovivaspecialtytherapeutics.com/publication/characterization-of-acinetobacter-baumannii-calcoaceticus-complex-isolates-and-microbiological-outcome-for-patients-treated-with-sulbactam-durlobactam-in-a-phase-3-trial-attack/2025-06-11T07:53:03-07:00https://innovivaspecialtytherapeutics.com/publication/comparison-of-clinical-outcomes-for-patients-with-monomicrobial-vs-polymicrobial-acinetobacter-baumannii-calcoaceticus-complex-infections-treated-with-sulbactam-durlobactam-or-colistin-a-subset-analy/2025-06-11T09:24:22-07:00https://innovivaspecialtytherapeutics.com/publication/sulbactam-durlobactam-a-%ce%b2-lactam-%ce%b2-lactamase-inhibitor-combination-targeting-acinetobacter-baumannii/2025-06-11T07:52:24-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-sulbactam-durlobactam-against-colistin-resistant-and-or-cefiderocol-non-susceptible-carbapenem-resistant-acinetobacter-baumannii-collected-in-u-s-hospitals/2025-06-11T07:52:07-07:00https://innovivaspecialtytherapeutics.com/publication/sulbactam-durlobactam-a-novel-drug-for-the-treatment-of-multidrug-resistant-acinetobacter-baumannii-infections-a-systematic-review/2025-06-11T07:51:35-07:00https://innovivaspecialtytherapeutics.com/publication/current-treatment-options-for-pneumonia-caused-by-carbapenem-resistant-acinetobacter-baumannii/2025-06-11T07:51:19-07:00https://innovivaspecialtytherapeutics.com/publication/cefiderocol-and-sulbactam-durlobactam-against-carbapenem-resistant-acinetobacter-baumannii/2025-06-11T07:51:02-07:00https://innovivaspecialtytherapeutics.com/publication/the-surgical-infection-society-guidelines-on-the-management-of-intra-abdominal-infection-2024-update/2025-06-11T09:23:44-07:00https://innovivaspecialtytherapeutics.com/publication/idsa-2024-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections/2025-06-11T07:49:18-07:00https://innovivaspecialtytherapeutics.com/publication/interactions-between-zoliflodacin-and-neisseria-gonorrhoeae-gyrase-and-topoisomerase-iv-enzymological-basis-for-cellular-targeting/2025-06-11T09:21:06-07:00https://innovivaspecialtytherapeutics.com/publication/molecular-drivers-of-resistance-to-sulbactam-durlobactam-in-contemporary-clinical-isolates-of-acinetobacter-baumannii/2025-06-11T07:49:55-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacometric-analyses-to-support-dose-selection-of-zoliflodacin-a-first-in-class-oral-antibiotic-being-developed-for-the-treatment-of-uncomplicated-gonorrhea/2025-06-11T09:32:54-07:00https://innovivaspecialtytherapeutics.com/publication/ex-vivo-assessment-of-sulbactam-durlobactam-clearance-during-continuous-renal-replacement-therapy-to-guide-dosing-recommendations/2025-06-11T07:48:08-07:00https://innovivaspecialtytherapeutics.com/publication/991/2025-06-11T09:35:40-07:00https://innovivaspecialtytherapeutics.com/publication/the-renin-angiotensin-aldosterone%e2%80%91system-in-sepsis-and-its-clinical-modulation-with-exogenous-angiotensin-ii/2025-06-11T11:08:03-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-for-catecholamine-resistant-vasodilatory-shock-in-patients-with-acute-kidney-injury-a-post-hoc-analysis-of-the-athos-3-trial/2025-06-11T10:18:38-07:00https://innovivaspecialtytherapeutics.com/publication/population-pharmacokinetic-analyses-for-sulbactam-durlobactam-using-phase-1-2-and-3-data/2025-06-11T07:48:41-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-zoliflodacin-against-contemporary-neisseria-gonorrhoeae-isolate-from-the-united-states/2025-06-11T09:22:29-07:00https://innovivaspecialtytherapeutics.com/publication/descriptive-analysis-of-sexually-transmitted-infections-risk-factors-among-participants-included-in-the-global-zoliflodacin-phase-3-clinical-trial/2025-06-11T09:22:56-07:00https://innovivaspecialtytherapeutics.com/publication/recommendations-for-the-optimal-introduction-of-novel-antibiotics-to-treat-uncomplicated-gonorrhoea-in-the-face-of-increasing-antimicrobial-resistance-a-case-study-with-zoliflodacin/2025-06-11T09:17:31-07:00https://innovivaspecialtytherapeutics.com/publication/oral-zoliflodacin-for-treatment-of-uncomplicated-gonorrhea-subgroup-analyses-by-sex-at-birth-race-and-region-of-a-global-phase-3-randomized-controlled-clinical-trial/2025-06-11T10:13:17-07:00https://innovivaspecialtytherapeutics.com/publication/oral-zoliflodacin-is-non-inferior-to-a-combination-of-ceftriaxone-and-azithromycin-for-treatment-of-uncomplicated-urogenital-gonorrhoea-results-of-a-large-global-phase-3-randomised-controlled-trial/2025-06-11T09:20:28-07:00https://innovivaspecialtytherapeutics.com/publication/zoliflodacin-addressing-a-growing-global-threat-through-a-novel-public-private-development-partnership/2025-06-11T09:12:54-07:00https://innovivaspecialtytherapeutics.com/publication/ceftobiprole-for-treatment-of-complicated-staphylococcus-aureus-bacteremia/2025-06-11T07:46:03-07:00https://innovivaspecialtytherapeutics.com/publication/ceftobiprole-compared-with-vancomycin-plus-aztreonam-in-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-results-of-a-phase-3-randomized-double-blind-trial-target/2025-06-11T07:46:29-07:00https://innovivaspecialtytherapeutics.com/publication/a-randomised-double-blind-trial-comparing-ceftobiprole-medocaril-with-ceftriaxone-with-or-without-linezolid-for-the-treatment-of-patients-with-community-acquired-pneumonia-requiring-hospitalisation/2025-05-02T09:58:53-07:00https://innovivaspecialtytherapeutics.com/publication/a-phase-3-randomized-investigator-blinded-trial-comparing-ceftobiprole-with-a-standard-of-care-cephalosporin-with-or-without-vancomycin-for-the-treatment-of-pneumonia-in-pediatric-patients/2025-06-11T09:12:19-07:00https://innovivaspecialtytherapeutics.com/publication/efficacy-and-safety-of-ceftobiprole-in-patients-aged-65-years-or-older-a-post-hoc-analysis-of-three-phase-iii-studies/2025-06-11T09:10:04-07:00https://innovivaspecialtytherapeutics.com/publication/athos-3-investigators-an-index-of-the-initial-blood-pressure-response-to-angiotensin-ii-treatment-and-its-association-with-clinical-outcomes-in-vasodilatory-shock/2025-06-11T09:09:49-07:00https://innovivaspecialtytherapeutics.com/publication/ceftobiprole-activity-against-multidrug-resistant-staphylococcus-aureus-clinical-isolates-collected-in-the-united-states-from-2016-through-2022/2025-05-02T09:55:39-07:00https://innovivaspecialtytherapeutics.com/publication/impact-of-obesity-on-clinical-outcomes-in-patients-treated-with-ceftobiprole-results-from-phase-3-clinical-trials/2025-06-11T07:44:18-07:00https://innovivaspecialtytherapeutics.com/publication/model-based-approach-for-optimizing-ceftobiprole-dosage-in-pediatric-patients/2025-05-01T09:36:59-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacokinetics-and-safety-of-ceftobiprole-in-pediatric-patients/2025-05-01T09:39:20-07:00https://innovivaspecialtytherapeutics.com/publication/a-microbiological-and-structural-analysis-of-the-interplay-between-sulbactam-durlobactam-and-imipenem-against-penicillin-binding-proteins-pbps-of-acinetobacter-spp/2025-06-11T09:13:45-07:00https://innovivaspecialtytherapeutics.com/publication/sulbactam-durlobactam-a-novel-antibiotic-combination-for-the-treatment-of-acinetobacter-baumannii-calcoaceticus-complex-abc-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial/2025-05-05T08:52:07-07:00https://innovivaspecialtytherapeutics.com/publication/an-overview-of-sulbactam-durlobactam-approval-and-implications-in-advancing-therapeutics-for-hospital-acquired-and-ventilator-associated-pneumonia-by-acinetobacter-baumannii-calcoaceticus-complex-a-n/2025-05-05T08:54:21-07:00https://innovivaspecialtytherapeutics.com/publication/sulbactam-durlobactam-for-the-treatment-of-acinetobacter-baumannii-calcoaceticus-complex/2025-05-05T08:57:06-07:00https://innovivaspecialtytherapeutics.com/publication/efficacy-and-safety-of-eravacycline-versus-tigecycline-for-complicated-intra-abdominal-infections-in-the-icu-a-multicenter-single-blind-parallel-randomized-controlled-trial-study-protocol/2025-06-11T09:18:39-07:00https://innovivaspecialtytherapeutics.com/publication/a-prospective-double-blind-randomised-controlled-trial-comparing-angiotensin-ii-to-norepinephrine-to-reduce-length-of-hospital-stay-in-cardiac-surgery-patients-the-porthos-study-protocol/2025-05-05T09:03:24-07:00https://innovivaspecialtytherapeutics.com/publication/a-prospective-double-blind-randomised-controlled-trial-comparing-angiotensin-ii-to-norepinephrine-to-reduce-length-of-hospital-stay-in-cardiac-surgery-patients-the-porthos-study-protocol-2/2025-06-11T09:09:15-07:00https://innovivaspecialtytherapeutics.com/publication/high-susceptibility-to-the-novel-antimicrobial-zoliflodacin-among-neisseria-gonorrhoeae-isolates-in-eight-who-enhanced-gonococcal-antimicrobial-surveillance-programme-countries-in-three-who-regions-2/2025-06-11T09:11:25-07:00https://innovivaspecialtytherapeutics.com/publication/ceftobiprole-a-therapeutic-update/2025-05-08T06:31:24-07:00https://innovivaspecialtytherapeutics.com/publication/association-between-timing-of-angiotensin-ii-administration-and-outcomes-in-vasoplegia-after-cardiac-surgery/2025-06-11T09:11:02-07:00https://innovivaspecialtytherapeutics.com/publication/evaluation-of-angiotensin-ii-in-patients-with-catecholamine-resistant-vasodilatory-shock-requiring-continuous-renal-replacement-therapy-angel-crrt/2025-06-11T09:10:35-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacokinetic-and-pharmacodynamic-evaluation-of-sulbactam-durlobactam-in-a-critically-ill-patient-on-continuous-venovenous-hemofiltration-infected-with-carbapenem-resistant-acinetobacter-baumannii-c/2025-06-11T07:47:25-07:00https://innovivaspecialtytherapeutics.com/publication/quantification-of-sulbactam-and-durlobactam-in-saline-and-human-plasma-via-ultra-performance-liquid-chromatography-tandem-mass-spectrometry/2025-06-11T07:35:10-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activities-of-zoliflodacin-and-solithromycin-against-neisseria-gonorrhoeae-isolates-from-korea/2025-06-11T07:39:00-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-ceftobiprole-against-20255-recent-clinical-bacterial-isolates-in-canada-canward-2015-2023-2/2025-06-11T07:41:04-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-ceftobiprole-against-prominent-methicillin-resistant-staphylococcus-aureus-clonal-groups-collected-through-the-sentry-antimicrobial-surveillance-program/2025-07-31T11:12:37-07:00https://innovivaspecialtytherapeutics.com/publication/update-on-the-activity-of-ceftobiprole-against-gram-positive-clinical-bacterial-isolates-causing-skin-and-skin-structure-infections-in-the-united-states-2016-2020/2025-07-31T15:07:52-07:00https://innovivaspecialtytherapeutics.com/publication/ceftobiprole-versus-ceftriaxone-%c2%b1-linezolid-in-community-acquired-bacterial-pneumonia-cabp-re-analysis-of-a-randomized-phase-3-study-using-2020-fda-guidance/2025-07-31T15:15:48-07:00https://innovivaspecialtytherapeutics.com/publication/population-pharmacokinetics-ppk-analysis-of-sulbactam-durlobactam-sud-to-support-dose-selection-for-evaluation-in-a-clinical-trial-in-pediatric-patients-with-acinetobacter-baumannii-calcoaceticus/2025-10-21T05:32:10-07:00https://innovivaspecialtytherapeutics.com/publication/population-pharmacokinetics-ppk-analysis-of-eravacycline-erv-to-support-the-dose-selection-for-a-trial-in-pediatric-patients-aged-8-to-less-than-18-years-with-complicated-intra-abdominal-infection/2025-10-21T05:33:53-07:00https://innovivaspecialtytherapeutics.com/publication/synergistic-cefiderocol-containing-antibiotic-combinations-active-against-highly-drug-resistant-acinetobacter-baumannii-patient-isolates-with-diverse-resistance-mechanisms/2025-10-10T08:48:38-07:00https://innovivaspecialtytherapeutics.com/publication/activity-of-ampicillin-sulbactam-sulbactam-durlobactam-and-comparators-against-acinetobacter-baumannii-calcoaceticus-complex-strains-isolated-from-respiratory-and-bloodstream-sources-results-from-a/2025-10-10T08:50:27-07:00https://innovivaspecialtytherapeutics.com/publication/pharmacokinetics-of-sulbactam-durlobactam-in-a-patient-with-acute-renal-failure-severe-obesity-and-carbapenem-resistant-acinetobacter-baumannii-bacteremia-a-case-report/2025-10-10T08:52:09-07:00https://innovivaspecialtytherapeutics.com/publication/amrrounds-carbapenem-resistant-acinetobacter-baumannii-in-the-intensive-care-unit-when-resistance-meets-severity/2025-10-10T08:56:24-07:00https://innovivaspecialtytherapeutics.com/publication/sulbactam-durlobactam-a-novel-antibiotic-combination-for-the-treatment-of-acinetobacter-baumannii-calcoaceticus-complex-abc-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-2/2025-10-10T08:55:46-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-ii-conventional-vasopressor-therapy-and-mortality-in-shock-a-large-multicenter-propensity-score-weighted-analysis/2025-10-10T08:57:38-07:00https://innovivaspecialtytherapeutics.com/publication/comparison-of-angiotensin-ii-giapreza-use-in-kidney-transplantation-between-black-and-non-black-patients/2025-10-10T08:58:39-07:00https://innovivaspecialtytherapeutics.com/publication/angiotensin-receptor-blockade-does-not-decrease-synthetic-angiotensin-ii-giapreza-effectiveness-in-perioperative-hypotension-surrounding-kidney-transplant/2025-10-10T09:04:26-07:00https://innovivaspecialtytherapeutics.com/publication/comparative-in-vitro-activity-of-sulbactam-with-avibactam-or-durlobactam-against-carbapenem-resistant-acinetobacter-baumannii/2025-11-19T10:13:39-08:00https://innovivaspecialtytherapeutics.com/publication/turning-the-tide-against-carbapenem-resistant-acinetobacter-baumannii-advancing-care-with-sulbactam-durlobactam/2025-11-19T10:17:56-08:00https://innovivaspecialtytherapeutics.com/publication/zoliflodacin-versus-ceftriaxone-plus-azithromycin-for-treatment-of-uncomplicated-urogenital-gonorrhoea-an-international-randomised-controlled-open-label-phase-3-non-inferiority-clinical-trial/2026-01-08T07:36:03-08:00https://innovivaspecialtytherapeutics.com/publication/clinical-efficacy-and-safety-of-eravacycline-for-the-treatment-of-enterococcal-infections-a-subpopulation-analysis/2026-01-08T07:39:12-08:00https://innovivaspecialtytherapeutics.com/publication/inference-of-ceftobiprole-susceptibility-through-surrogate-testing-of-ceftaroline/2026-02-25T10:12:35-08:00https://innovivaspecialtytherapeutics.com/publication/ceftobiprole-and-the-kidney-secondary-analyses-of-the-eradicate-s-aureus-bacteraemia-trial/2026-03-04T13:27:24-08:00https://innovivaspecialtytherapeutics.com/publication/real-world-use-of-eravacycline-for-the-treatment-of-mono-and-polymicrobial-infections-involving-enterobacterales/2026-03-23T09:55:24-07:00https://innovivaspecialtytherapeutics.com/publication/thromboembolic-events-in-the-angiotensin-ii-for-the-treatment-of-high-output-shock-phase-3-trial/2026-04-30T12:35:50-07:00https://innovivaspecialtytherapeutics.com/publication/a-multi-site-study-comparing-a-commercially-prepared-dried-mic-susceptibility-system-to-the-clsi-iso-broth-microdilution-method-for-sulbactam-durlobactam-se4-using-acinetobacter-spp/2026-05-01T09:14:40-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-antimicrobial-activity-of-ceftobiprole-and-comparator-agents-against-streptococcus-pneumoniae-responsible-for-lower-respiratory-tract-infections-in-the-united-states-2016-2020-including-re/2026-05-04T12:49:51-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitroactivity-of-sulbactam-durlobactam-against-global-clinical-acinetobacter-baumannii-calcoaceticus-complex-isolates-collected-in-2024/2026-05-05T07:51:06-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-ceftobiprole-against-gram-positive-clinical-bacterial-isolates-causing-skin-and-skin-structure-infections-in-the-united-states/2026-06-03T13:30:29-07:00https://innovivaspecialtytherapeutics.com/publication/in-vitro-activity-of-zoliflodacin-against-neisseria-gonorrhoeae-collected-in-the-united-states-from-2020-to-2022/2026-08-06T07:14:35-07:00https://innovivaspecialtytherapeutics.com/publication/zoliflodacin-first-approval/2026-08-11T12:35:33-07:00